AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Pharmaceutical Companies

574.216

+10.5541.87%

Number of Gainers:13

Number of Losers:13

Number of Flat:19

PE:- -

High:574.959

Open:565.837

Low:561.751

Close:563.662

Volume:49.61M

Turnover:90.26M

Market Cap:78.87B

Float Cap:76.13B

Loading ...

BRIEF-Monash IVF Group Appoints Birol Akdogan As Interim CFO

BUZZ-Australia's Racura Oncology gains on Purdue University cancer study collab

Monash IVF Group Appoints Interim CFO

MT Newswires Live

Monash IVF Group Ltd-Appointment of Interim CFO

THOMSON REUTERS

Here's one reason why experts think the CSL share price can rise 65%!

A Look At Hexcel (HXL) Valuation After CFO Change And Falcon 10X Supplier Spotlight

Simply Wall St.

Asian Equities Traded in the US as American Depositary Receipts Surge in Wednesday Trading

MT Newswires Live

$5,000 invested in CSL shares 12 months ago is now worth…

3 top blue-chip ASX 200 shares that look dirt cheap right now

Polynovo Ltd-Director Appointment - Charmaine Gittleson

THOMSON REUTERS

BRIEF-Genetic Technologies To Not Proceed With Ellerfield Wealth Acquisition

Genetic Technologies Ltd - Board Discontinues Acquisition Discussions, to Focus on Relisting Strategy Opportunities

THOMSON REUTERS

Genetic Technologies Ltd - to Not Proceed With Ellerfield Wealth Acquisition

THOMSON REUTERS

Mesoblast files Form 3 initial beneficial ownership statement for director Gregory George

Forget CSL shares, this ASX healthcare stock could double in value

Assessing Carlisle Companies (CSL) Valuation After Recent Share Price Pullback

Simply Wall St.

3 top ASX shares that could double in value from here

These are the 10 most shorted ASX shares

How to survive an ASX share market crash

CSL shares look primed to take off — Here's why

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK7508/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK7508","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","market":"AU","secType":"PLATE","nameCN":"Pharmaceutical Companies","latestPrice":574.21606,"timestamp":1774498783452,"preClose":563.6616,"halted":0,"volume":49611302,"delay":0,"changeRate":0.018725,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":10.554443,"latestTime":"03-26 15:19:44 AEDT","open":565.8373,"high":574.95935,"low":561.751,"amount":90257120,"amplitude":0.023433,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1774501200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1774479600000,1774501200000]],"turnoverRate":0.001906,"increases":14,"decrements":13,"flats":16,"marketCap":78866434274.75,"floatMarketCap":76132962627.1875},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","high":574.95935,"amplitude":0.023433,"preClose":563.6616,"low":561.751,"latestPrice":574.21606,"volume":49611302,"delay":0,"open":565.8373,"prevYearClose":644.3692,"prevWeekClose":551.995,"prevMonthClose":592.49,"prevQuarterClose":644.369,"fiveDayClose":539.082,"twentyDayClose":592.019,"sixtyDayClose":643.256,"secType":"PLATE","market":"AU","turnoverRate":0.001906,"marketCap":78866434274.75,"floatMarketCap":76132962627.1875,"timestamp":1774498783452,"nameCN":"Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK7508\",,,,undefined,":{"bkCode":"BK7508","up":13,"down":13,"flat":19},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK7508\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2622886755","title":"BRIEF-Monash IVF Group Appoints Birol Akdogan As Interim CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2622886755","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622886755?lang=en_us&edition=fundamental","pubTime":"2026-03-26 08:50","pubTimestamp":1774486236,"startTime":"0","endTime":"0","summary":"BRIEF-Monash IVF Group Appoints Birol Akdogan As Interim CFO March 26 (Reuters) - Monash IVF Group Ltd MVF.AX:APPOINTMENT OF INTERIM CFOAPPOINTS BIROL AKDOGAN AS INTERIM CFO EFFECTIVE 26 MARCH 2026Further company coverage: MVF.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nTUE5CYMJY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MVF.AU","BK7113","BK7508"],"gpt_icon":0},{"id":"2622886879","title":"BUZZ-Australia's Racura Oncology gains on Purdue University cancer study collab","url":"https://stock-news.laohu8.com/highlight/detail?id=2622886879","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622886879?lang=en_us&edition=fundamental","pubTime":"2026-03-26 08:30","pubTimestamp":1774485045,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Racura Oncology gains on Purdue University cancer study collab** Racura Oncology RAC.AX rises as much as 4% to A$2.85, highest since March 25** Biopharma co commences research collabo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nL6N40E00Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","RAC.AU"],"gpt_icon":0},{"id":"2622688349","title":"Monash IVF Group Appoints Interim CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2622688349","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622688349?lang=en_us&edition=fundamental","pubTime":"2026-03-26 07:39","pubTimestamp":1774481994,"startTime":"0","endTime":"0","summary":"Monash IVF Group  appointed Birol Akdogan as interim chief financial officer, effective Thursday, according to a same-day filing with the Australian bourse.Akdogan will succeed Malik Janudin, who will stay with the company until April 2 to ensure a smooth and orderly transition, the filing added.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7113","LU1670710588.SGD","MVF.AU","VFC","BK4588","BK4504","BK4585","LU1670710661.SGD","BK4082","BK4202","LU1670711040.USD","LU1670711123.USD","IVF","BK7508"],"gpt_icon":0},{"id":"2622467007","title":"Monash IVF Group Ltd-Appointment of Interim CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2622467007","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622467007?lang=en_us&edition=fundamental","pubTime":"2026-03-26 05:17","pubTimestamp":1774473478,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nTUE5CYMJY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MVF.AU","BK7508","BK7113"],"gpt_icon":0},{"id":"2622007554","title":"Here's one reason why experts think the CSL share price can rise 65%!","url":"https://stock-news.laohu8.com/highlight/detail?id=2622007554","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622007554?lang=en_us&edition=fundamental","pubTime":"2026-03-26 05:00","pubTimestamp":1774472400,"startTime":"0","endTime":"0","summary":"The CSL Ltd  share price has taken a dive over the last several months. As the chart below shows, it has fallen almost 50% from August 2025. But, experts think there's a chance that the ASX healthcare share could recover a lot of the lost ground.The global biotech business provides a number of healthcare products, including blood plasma-related treatments and vaccines.UBS recently released a note that outlined one of the reasons why investors can be excited by the business.The broker said that there has been a rapid uptake of CSL's Andembry since the launch in mid-2025, with more than 1,000 patients on the therapy. UBS estimates this is around 15% of patients on prophylactic treatment across the major markets where it has been approved.At a US price of around $400,000, the broker said this early momentum should underpin \"strong second-half FY26 sales and extend into FY27\".UBS suggests that its hereditary angioedema  forecasts may prove conservative, as it has allowed for competitive pr","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/26/heres-one-reason-why-experts-think-the-csl-share-price-can-rise-65/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2026/03/26/heres-one-reason-why-experts-think-the-csl-share-price-can-rise-65/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["LU0205194284.USD","LU1169589451.USD","BK4118","LU1863844749.USD","IE0034235071.USD","LU0205193047.USD","SG9999004303.SGD","SGXZ23171101.USD","LU0012050646.USD","CSL","LU0728928796.USD","BK4086","BK7067","LU1863844665.USD","LU1829250122.USD","BK7511","BK4198","BK4585","LU0106261612.USD","IE00BLDYK493.USD","BK7508","LU3187612489.SGD","CSL.AU","UBS","BK4534","BK7501","HAE","BK4588","IE00B19Z6F94.USD","IE0034390439.USD","IE00B64QTZ34.USD","LU1169590202.USD"],"gpt_icon":0},{"id":"2622001331","title":"A Look At Hexcel (HXL) Valuation After CFO Change And Falcon 10X Supplier Spotlight","url":"https://stock-news.laohu8.com/highlight/detail?id=2622001331","media":"Simply Wall St.","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622001331?lang=en_us&edition=fundamental","pubTime":"2026-03-26 02:09","pubTimestamp":1774462163,"startTime":"0","endTime":"0","summary":"Why Hexcel’s CFO transition and Falcon 10X role matter for investors\nHexcel (HXL) has two fresh storylines for investors to weigh: a new Chief Financial Officer with deep aerospace experience, and a reinforced role as a key materials supplier on Dassault’s Falcon 10X business jet program.\nSee our latest analysis for Hexcel.\nRecent trading tells a mixed story, with a 2.09% 1 day share price return and a 5.25% year to date share price return set against a 10.03% 1 month share price decline. At...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/3021000-choice1-main-header/1585186644732","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/3021000-choice1-main-header/1585186644732"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/capital-goods/nyse-hxl/hexcel/news/a-look-at-hexcel-hxl-valuation-after-cfo-change-and-falcon-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/capital-goods/nyse-hxl/hexcel/news/a-look-at-hexcel-hxl-valuation-after-cfo-change-and-falcon-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0053671581.USD","HXL","LU0205194284.USD","LU0205193047.USD","HXL.AU","LU0240877869.USD","BK4187","BK7067","LU0240878834.USD","BK7508"],"gpt_icon":0},{"id":"2622072954","title":"Asian Equities Traded in the US as American Depositary Receipts Surge in Wednesday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2622072954","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622072954?lang=en_us&edition=fundamental","pubTime":"2026-03-25 22:28","pubTimestamp":1774448895,"startTime":"0","endTime":"0","summary":"Asian equities traded in the US as American depositary receipts were tracking sharply higher Wednesday morning, rising 2.10% to 2,670.87 on the S&P Asia 50 ADR Index.From North Asia, the gainers were led by brand platform Baozun  and travel company Tuniu , which climbed 12% and 6.1%, respectively. They were followed by computer hardware maker Canaan  and online discount retailer Vipshop , which advanced 5.8% and 4.9%, respectively.The decliners from North Asia were led by wealth management firm Noah  and mobile big data platform Aurora Mobile , which fell 4.6% and 4.4%, respectively. They were followed by education company 17 Education & Technology Group  and semiconductor company Silicon Motion Technology , which dropped 2.9% and 2.5%, respectively.From South Asia, the gainers were led by tech conglomerate Sea  and lender HDFC Bank , which rose 4.6% and 3.9%, respectively. They were followed by pharmaceutical company Dr. Reddy's Laboratories  and telecommunications operator Telekomuni","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BZUN","LU2045819591.USD","VIPS","SG9999013460.SGD","SE","LU2089985449.USD","LU2177674079.SGD","SG9999006266.SGD","BK4502","AFG","CAN","LU1791710400.SGD","LU2065171402.SGD","LU0441851309.USD","LU0572940350.SGD","LU0630378692.HKD","LU1854103824.USD","BK7508","LU1115378108.SGD","HDB","LU2125910849.SGD","LU0499858602.USD","LU1048588211.SGD","BK4023","YQ","RDY.AU","LU1839390173.USD","LU0499858438.USD","LU0210637038.USD","LU0264606111.USD","BK4170","LU2125910500.SGD","RDY","LU0979878070.USD","IE0031814969.USD","LU0532188223.SGD","LU0541502299.USD","SG9999004360.SGD","LU0287143357.SGD","JG","IE00B7N09G41.SGD","TLK","TOUR","BK4509","SIMO","LU0797268264.HKD","NOAH","LU0589944569.HKD","LU0708995666.HKD","CAN.AU"],"gpt_icon":1},{"id":"2622043678","title":"$5,000 invested in CSL shares 12 months ago is now worth…","url":"https://stock-news.laohu8.com/highlight/detail?id=2622043678","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622043678?lang=en_us&edition=fundamental","pubTime":"2026-03-25 10:31","pubTimestamp":1774405911,"startTime":"0","endTime":"0","summary":"CSL Ltd  shares are in the green in Wednesday lunchtime trade. At the time of writing, the shares are up 1.2% to $141 a piece. In fact, over the past five days, the biotech company's stock price has continually climbed, now up 4%.It's great news for investors, as the beaten-down stock's share price has crashed significantly over the past 18 months. Several headwinds, including lacklustre financial results, a surprise restructure announcement, a shock CEO exit and revised revenue guidance, all helped push the share price down.Concerns around margins and broad market conditions haven't helped the biotech company's shares either. Healthcare stocks have lagged in 2026 as investors shift towards the resources and energy sectors.At the time of writing, the S&P/ASX 200 Health Care Index  is down 5% over the past month and 17.5% for the year-to-date.For context, the S&P/ASX 200 Index  is down 5.2% over the past month and 1.8% year-to-date.Meanwhile, $5,000 invested in the company's shares when","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/25/5000-invested-in-csl-shares-12-months-ago-is-now-worth/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2026/03/25/5000-invested-in-csl-shares-12-months-ago-is-now-worth/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["XJO.AU","BK7508","CSL","BK4086","SGXZ23171101.USD","LU0728928796.USD","LU1169589451.USD","BK7511","LU1169590202.USD","BK7501","BK7067","CSL.AU","SG9999004303.SGD"],"gpt_icon":0},{"id":"2622016321","title":"3 top blue-chip ASX 200 shares that look dirt cheap right now","url":"https://stock-news.laohu8.com/highlight/detail?id=2622016321","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622016321?lang=en_us&edition=fundamental","pubTime":"2026-03-25 05:29","pubTimestamp":1774387785,"startTime":"0","endTime":"0","summary":"A number of popular blue-chip ASX 200 shares recently hit 52-week lows or worse. While this is disappointing, it could have created a buying opportunity for patient investors. For example, listed belo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/25/3-top-blue-chip-asx-200-shares-that-look-dirt-cheap-right-now/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2026/03/25/3-top-blue-chip-asx-200-shares-that-look-dirt-cheap-right-now/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK4535","BK7007","BK7097","BK4588","CSL.AU","TWE.AU","BK7511","BK7508","BK4585","COH.AU","BK7505","BK7067","BK7501"],"gpt_icon":0},{"id":"2621105107","title":"Polynovo Ltd-Director Appointment - Charmaine Gittleson","url":"https://stock-news.laohu8.com/highlight/detail?id=2621105107","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621105107?lang=en_us&edition=fundamental","pubTime":"2026-03-24 15:41","pubTimestamp":1774338109,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nTUE3W4KVP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7126","PNV.AU"],"gpt_icon":0},{"id":"2621390310","title":"BRIEF-Genetic Technologies To Not Proceed With Ellerfield Wealth Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2621390310","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621390310?lang=en_us&edition=fundamental","pubTime":"2026-03-24 09:40","pubTimestamp":1774316409,"startTime":"0","endTime":"0","summary":"BRIEF-Genetic Technologies To Not Proceed With Ellerfield Wealth AcquisitionMarch 24 (Reuters) - Genetic Technologies Ltd GTG.AX:TO NOT PROCEED WITH ELLERFIELD WEALTH ACQUISITIONBOARD DISCONTINUES ACQ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nFWN40B11F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7048","GTG.AU"],"gpt_icon":0},{"id":"2621211039","title":"Genetic Technologies Ltd - Board Discontinues Acquisition Discussions, to Focus on Relisting Strategy Opportunities","url":"https://stock-news.laohu8.com/highlight/detail?id=2621211039","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621211039?lang=en_us&edition=fundamental","pubTime":"2026-03-24 09:34","pubTimestamp":1774316062,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nFWN40B11F:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GTG.AU","BK7508","BK7048"],"gpt_icon":0},{"id":"2621039219","title":"Genetic Technologies Ltd - to Not Proceed With Ellerfield Wealth Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2621039219","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621039219?lang=en_us&edition=fundamental","pubTime":"2026-03-24 09:34","pubTimestamp":1774316062,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nFWN40B11F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GTG.AU","BK7508","BK7048"],"gpt_icon":0},{"id":"2621503328","title":"Mesoblast files Form 3 initial beneficial ownership statement for director Gregory George","url":"https://stock-news.laohu8.com/highlight/detail?id=2621503328","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621503328?lang=en_us&edition=fundamental","pubTime":"2026-03-24 08:00","pubTimestamp":1774310455,"startTime":"0","endTime":"0","summary":"Mesoblast director George Gregory filed an initial beneficial ownership statement reporting 5 ordinary shares held directly.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mesoblast Limited published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 23, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL8thSHp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","MSB.AU","BK7501","BK7067"],"gpt_icon":0},{"id":"2621087017","title":"Forget CSL shares, this ASX healthcare stock could double in value","url":"https://stock-news.laohu8.com/highlight/detail?id=2621087017","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621087017?lang=en_us&edition=fundamental","pubTime":"2026-03-24 05:50","pubTimestamp":1774302657,"startTime":"0","endTime":"0","summary":"It hasn't been a great year for investors in CSL Ltd  shares.The biotech giant — long considered a market darling — has seen its shares slide roughly 20% in 2026 so far. A softer-than-expected half-year result rattled confidence, and growing competition hasn't helped sentiment.But while CSL works through its challenges, investors might want to look elsewhere in the healthcare space.One name stands out: Pro Medicus Ltd . It hasn't been immune to selling pressure either, with shares down around 46% this year. Yet brokers are tipping explosive upside from here.Pro Medicus is the third-largest healthcare stock on the ASX, sitting behind ResMed  and CSL shares.It has also locked in long-term contracts with large hospital networks, particularly in the US. That creates sticky, recurring revenue streams — something investors love.CSL shares still have upside, but it's more modest. The average 12-month price target sits at $209.50, pointing to roughly 50% gains. Even the more cautious forecasts","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/24/forget-csl-shares-this-asx-healthcare-stock-could-double-in-value/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2026/03/24/forget-csl-shares-this-asx-healthcare-stock-could-double-in-value/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["CSL","LU0728928796.USD","SGXZ23171101.USD","CSL.AU","LU1169589451.USD","SG9999004303.SGD","BK7511","BK7007","RMD.AU","BK7501","BK7508","PME.AU","BK7067","LU1169590202.USD","BK7094","BK4086"],"gpt_icon":0},{"id":"2621256277","title":"Assessing Carlisle Companies (CSL) Valuation After Recent Share Price Pullback","url":"https://stock-news.laohu8.com/highlight/detail?id=2621256277","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621256277?lang=en_us&edition=fundamental","pubTime":"2026-03-23 08:20","pubTimestamp":1774225244,"startTime":"0","endTime":"0","summary":"Recent share performance puts Carlisle Companies (CSL) under the microscope\nCarlisle Companies (CSL) has been on many investors’ radars after a one-month return of about a 20% decline and a past three-month move of roughly a 1% decline, prompting closer attention to its fundamentals.\nSee our latest analysis for Carlisle Companies.\nThat recent 20% one month share price decline and 4.1% seven day share price return decline comes after a much stronger long run, with a 3 year total shareholder...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/3061000-choice1-main-header/1585186603448","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/3061000-choice1-main-header/1585186603448"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/capital-goods/nyse-csl/carlisle-companies/news/assessing-carlisle-companies-csl-valuation-after-recent-shar-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/capital-goods/nyse-csl/carlisle-companies/news/assessing-carlisle-companies-csl-valuation-after-recent-shar-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","BK7511","LU0728928796.USD","BK7501","CSL","BK7508","LU1169590202.USD","BK4086","LU1169589451.USD","CSL.AU","SG9999004303.SGD","SGXZ23171101.USD"],"gpt_icon":0},{"id":"2621744550","title":"3 top ASX shares that could double in value from here","url":"https://stock-news.laohu8.com/highlight/detail?id=2621744550","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621744550?lang=en_us&edition=fundamental","pubTime":"2026-03-23 06:27","pubTimestamp":1774218446,"startTime":"0","endTime":"0","summary":"It's been a rough stretch for some of the most talked-about ASX shares. But here's the twist: while share prices have slid or stalled, broker optimism hasn't. In fact, it's surging.Three ASX shares stand out right now: Mesoblast Ltd , Telix Pharmaceuticals Ltd , and Zip Co Ltd . All three have had turbulent months. Yet analysts see massive upside, in some cases, more than a double from here.This ASX share has had a shaky start to the year, with the share price down about 25%. That's nothing new for this high-risk biotech stock. Volatility comes with the territory.Analyst outlook: This is where things get interesting. Brokers have an average price target on the ASX share of $4.23 at the time of writing. That implies around 105% upside. In other words, analysts believe a doubling is firmly on the table if execution improves.Analyst outlook: Despite all that, brokers are highly optimistic. The average price target is $4.21. That's about 191% upside — nearly triple its current share price.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/23/3-top-asx-shares-that-could-double-in-value-from-here/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2026/03/23/3-top-asx-shares-that-could-double-in-value-from-here/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7508","TLX.AU","BK7093","MSB.AU","BK7501","BK7067","ZIP.AU"],"gpt_icon":0},{"id":"2621774129","title":"These are the 10 most shorted ASX shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2621774129","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621774129?lang=en_us&edition=fundamental","pubTime":"2026-03-23 05:54","pubTimestamp":1774216455,"startTime":"0","endTime":"0","summary":"At the start of each week, I like to look atASIC's short position reportto find out which shares are being targeted by short sellers.This is because I believe it is well worth keeping a close eye on short interest levels as high levels can sometimes be a sign that something isn't quite right with a company.With that in mind, here are the 10 most shorted shares on the ASX this week according to ASIC:. Domino's Pizza Enterprises Ltd  continues to be the most shorted ASX share with short interest of 16%. This is up week on week. Short sellers appear doubtful that the struggling pizza chain operator's turnaround strategy will be a success.Treasury Wine Estates Ltd  has seen its short interest rise again to 15.1%. This wine giant has been battling very tough trading conditions, with consumers focusing on value rather than its premium wines.Flight Centre Travel Group Ltd  has short interest of 10.3%, which is up week on week. There are concerns that the travel agent won't deliver on its reve","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/23/these-are-the-10-most-shorted-asx-shares-23-march-2026/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2026/03/23/these-are-the-10-most-shorted-asx-shares-23-march-2026/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["IEL.AU","BK7505","DMP.AU","BK7097","FLT.AU","LYC.AU","BK7083","BK7503","BK7507","BK7067","BK7070","BK7508","TWE.AU","BK7126","GYG.AU","PNV.AU","NAN.AU","BK7137","BOE.AU","BK7132","BK7095","TLX.AU"],"gpt_icon":0},{"id":"2621494057","title":"How to survive an ASX share market crash","url":"https://stock-news.laohu8.com/highlight/detail?id=2621494057","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621494057?lang=en_us&edition=fundamental","pubTime":"2026-03-23 04:32","pubTimestamp":1774211560,"startTime":"0","endTime":"0","summary":"Market crashes never feel good. Even if you know they're a normal part of investing, seeing your ASX share portfolio fall can be uncomfortable. It can make you question your strategy and tempt you to act at exactly the wrong time. But the way you respond during a downturn often matters more than anything you do when markets are rising. Here's how I think about getting through it. Image source: Getty Images Accept that volatility is part of the process The first step is understanding that market declines aren't unusual. They happen regularly, even in strong long-term bull markets. Corrections, bear markets, and sudden selloffs are all part of the journey. Trying to avoid them completely usually leads to worse outcomes, because it often means sitting on the sidelines when markets recover. For me, accepting volatility upfront makes it easier to stay calm when it inevitably arrives. Focus on the businesses, not the share prices When markets fall, prices move quickly. But businesses don't c","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/23/how-to-survive-an-asx-share-market-crash/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2026/03/23/how-to-survive-an-asx-share-market-crash/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7067","BK7099","BK7511","BK7155","BK7508","BK7510","CSL.AU","BK7501","GMG.AU"],"gpt_icon":0},{"id":"2621316745","title":"CSL shares look primed to take off — Here's why","url":"https://stock-news.laohu8.com/highlight/detail?id=2621316745","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621316745?lang=en_us&edition=fundamental","pubTime":"2026-03-23 02:00","pubTimestamp":1774202400,"startTime":"0","endTime":"0","summary":"Another encouraging sign for investors is the outlook from analysts. Broker sentiment on CSL remains broadly positive, with most maintaining buy or outperform ratings on the stock. The average 12-month price target currently sits at roughly $211.00, implying potential upside of around 53% from current levels. Some forecasts are even more bullish, with the most optimistic broker suggesting the shares could rally as much as 99%. That's a strong vote of confidence in CSL's long-term growth prospects. What are the risks?Of course, CSL shares aren't without risks. The company has faced headwinds in recent years, including margin pressure, integration challenges, and currency impacts. Any delays in earnings recovery or weaker-than-expected growth could weigh on the share price. There's also the broader issue of market sentiment. High-quality healthcare stocks can still fall out of favour, particularly when investors rotate into other sectors. Foolish Takeaway CSL shares have been heavily sol","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/23/csl-shares-look-primed-to-take-off-heres-why/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2026/03/23/csl-shares-look-primed-to-take-off-heres-why/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["CSL","BK7508","SG9999004303.SGD","LU1169589451.USD","SGXZ23171101.USD","BK7511","BK7501","BK4086","LU1169590202.USD","XJO.AU","CSL.AU","BK7067","LU0728928796.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":1,"totalSize":127,"code":"91000000","status":"200"}]}}